Alembic Gets USFDA Approval; Shares Rise 3.36%

Mumbai, April 7: Alembic Pharmaceuticals Limited has secured final approval from the US Food and Drug Administration for its Dapagliflozin tablets in 5 mg and 10 mg strengths.

Dapagliflozin is not a niche product. It sits in a large, established therapy area. Used in the treatment of type 2 diabetes and increasingly in heart-related conditions, it has become part of mainstream chronic care.

The company’s product is therapeutically equivalent to AstraZeneca’s Farxiga. More importantly, Alembic was among the early filers with a paragraph IV certification. It makes the company eligible for 180 days of shared exclusivity. Even when shared, that window can shape early revenues in a meaningful way.

The opportunity itself is sizeable. The company has pegged the market at around US$10.48 billion for the 12 months ended December 2025.

Stock Market Snapshot

Alembic Pharmaceuticals share price moved up sharply as investors began factoring in the potential upside from the approval.

As of 13:22 IST on April 7, 2026, the stock was trading at ₹678.00, up ₹22.05 or 3.36% from the previous close of ₹655.95, according to exchange data.

The stock opened close to the previous levels and gradually climbed through the session, touching ₹683.00 before easing slightly.

Why This Approval Carries Weight

In the pharmaceutical business, approvals are routine. What makes this development relevant is the combination of three factors. A large addressable market, a widely prescribed molecule, and a limited window of competition at launch.

Dapagliflozin has seen expanding use cases beyond diabetes, particularly in cardiovascular care. Add to that the shared exclusivity period, and the early phase of launch becomes critical. Pricing, market entry timing, and supply readiness will all influence outcomes.

For Alembic, this is not just another addition to the portfolio. It is a product that can contribute meaningfully if executed well.

Company Background And Pipeline Strength

Alembic Pharmaceuticals Limited has built a steady presence in the US generics market over the years.

With this approval, the company’s cumulative ANDA approvals reach 235, including 217 final approvals. That number reflects consistency in filings and regulatory follow-through.

The US remains a key geography. But it is also competitive. Success depends not just on approvals, but on choosing the right products and timing entry effectively.

Alembic’s pipeline suggests it understands that balance.

Conclusion

This approval fits into a broader pattern. Consistent filings, selective opportunities, and steady expansion in the US market.

But within that pattern, some approvals stand out. This appears to be one of them.

The market has responded accordingly. The next phase, as always, will depend on execution. Launch timing, pricing strategy, and competitive intensity.

Source:

• https://www.nseindia.com/get-quote/equity/APLLTD/Alembic-Pharmaceuticals-Limited
• https://nsearchives.nseindia.com/corporate/APLLTD_07042026122413_Intimation_to_SE_Press_Release_FA_signed.pdf